Biosimilars Forum Praises FTC and FDA Action to Fight Anticompetitive Behaviors Blocking Access to Lower Cost Biosimilars
Washington, D.C. – Today the Federal Trade Commission Chairman Joseph J. Simons and FDA Commissioner Stephen M. Hahn, M.D. signed a joint statement announcing that the two agencies “are collaborating to support appropriate adoption of biosimilars, deter false or misleading statements about biosimilars, and deter anticompetitive behaviors in this industry.” The joint statement outlines the joint steps they will take to address these barriers, which have been blocking patient access to FDA-approved, safe, effective and lower-cost biosimilars.
“Increased biosimilar use in the U.S. can unlock billions of dollars in potential savings, but rampant misinformation and misaligned market and regulatory policies have stifled competition of these lower cost, life-changing medicines, which ultimately limits patients’ access. We applaud the FDA and FTC for joining together to dispel misinformation and address anticompetitive behavior to promote competition and drive innovation and health care savings for taxpayers,” said Juliana Reed.